Acute myeloid leukemia drug development in the post‐venetoclax era
Sign Up to like & getrecommendations! Published in 2019 at "American Journal of Hematology"
DOI: 10.1002/ajh.25556
Abstract: Much has been written and discussed related to the recent plethora of drug approvals by the United States Food and Drug Administration (FDA) for acute myeloid leukemia (AML). This topic has been met with appropriate… read more here.
Keywords: drug development; venetoclax; myeloid leukemia; drug ... See more keywords
Clinical and genetic characteristics predict outcomes of acute myeloid leukemia patients with FLT3 mutations receiving venetoclax‐based therapy
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Medicine"
DOI: 10.1002/cam4.6885
Abstract: Acute myeloid leukemia (AML) is a heterogeneous disease, and its heterogeneity is associated with treatment response. Despite the demonstrated success of venetoclax (VEN)‐based therapy for AML, the effect of FLT3 mutations on the efficacy of… read more here.
Keywords: acute myeloid; flt3 mutations; based therapy; venetoclax ... See more keywords
Relationship between venetoclax exposure, rituximab coadministration, and progression‐free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy
Sign Up to like & getrecommendations! Published in 2017 at "Hematological Oncology"
DOI: 10.1002/hon.2373
Abstract: Venetoclax is indicated at a dosage of 400 mg daily (QD) for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion who have received at least 1 prior therapy. Ongoing trials are… read more here.
Keywords: pfs; venetoclax; rituximab coadministration; effect ... See more keywords
Venetoclax plus bortezomib and dexamethasone in heavily pretreated end‐stage myeloma patients without t(11;14): A real‐world cohort
Sign Up to like & getrecommendations! Published in 2020 at "Hematological Oncology"
DOI: 10.1002/hon.2736
Abstract: Multiple myeloma (MM) is the second most common blood cancer caused by the uncontrolled proliferation of clonal plasma cells. Despite recent advances in treatment, a majority of patients eventually relapse and die because of progressive… read more here.
Keywords: venetoclax; myeloma; bortezomib dexamethasone; bortezomib ... See more keywords
Real-world evidence on venetoclax in chronic lymphocytic leukemia: The Italian experience.
Sign Up to like & getrecommendations! Published in 2023 at "Hematological oncology"
DOI: 10.1002/hon.3122
Abstract: Chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia in the western world. In Italy, venetoclax was approved for use in patients with CLL as monotherapy in 2017 and in combinations in… read more here.
Keywords: world; lymphocytic leukemia; venetoclax; chronic lymphocytic ... See more keywords
The Bcl‐2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Cellular Physiology"
DOI: 10.1002/jcp.28091
Abstract: Induction of reactive oxygen species (ROS), an important process for the cytotoxicity of various acute myeloid leukemia (AML) therapies including hypomethylating agents (HMAs), concurrently activates the NF‐E2‐related factor 2 (Nrf2) antioxidant response pathway which in… read more here.
Keywords: venetoclax; nrf2 antioxidant; treatment; hypomethylating agents ... See more keywords
Venetoclax-resistant CLL cells show a highly activated and proliferative phenotype
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Immunology, Immunotherapy"
DOI: 10.1007/s00262-021-03043-x
Abstract: Venetoclax treatment has demonstrated efficacy and a safety profile in chronic lymphocytic leukemia (CLL) patients, however the emergence of resistant cells is a current complication. We and others, previously reported that the activation of CLL… read more here.
Keywords: phenotype; resistant cll; cll; venetoclax ... See more keywords
Efficacy of venetoclax combined with homoharringtonine and cytarabine for younger adults with newly diagnosed AML
Sign Up to like & getrecommendations! Published in 2025 at "Annals of Hematology"
DOI: 10.1007/s00277-025-06250-z
Abstract: Venetoclax (VEN)--based induction therapy has demonstrated considerable promise in treating acute myeloid leukemia (AML); however, the optimal VEN-based combination therapy remains to be established. This study evaluated the efficacy and safety of the venetoclax-homoharringtonine-cytarabine (VHA)… read more here.
Keywords: newly diagnosed; aml; efficacy; homoharringtonine cytarabine ... See more keywords
Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk follicular lymphoma as front-line therapy: PrE0403
Sign Up to like & getrecommendations! Published in 2025 at "Blood Cancer Journal"
DOI: 10.1038/s41408-025-01300-1
Abstract: Over-expression of BCL-2 defines follicular lymphoma (FL). Venetoclax (VEN), a selective BCL-2 inhibitor, has previously been evaluated with bendamustine-based chemoimmunotherapy. VEN was given continuously, resulting in promising efficacy but unacceptable toxicity. The Phase II PrE0403… read more here.
Keywords: follicular lymphoma; risk; high risk; phase ... See more keywords
Development of venetoclax with 2-hydroxypropyl-beta-cyclodextrin inclusion complex for improved bioavailability
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Biomolecular Structure and Dynamics"
DOI: 10.1080/07391102.2024.2305695
Abstract: Abstract Cyclodextrin complexes loaded with venetoclax for improved solubility and therapeutic efficacy as repurposed drug. The venetoclax-cyclodextrin inclusion complex was prepared using kneading method. Primarily in-silico molecular docking study was performed to examine the possible… read more here.
Keywords: cyclodextrin inclusion; venetoclax hydroxypropyl; inclusion; inclusion complex ... See more keywords
An update on the efficacy of Venetoclax for chronic lymphocytic leukemia.
Sign Up to like & getrecommendations! Published in 2023 at "Expert opinion on pharmacotherapy"
DOI: 10.1080/14656566.2023.2218545
Abstract: INTRODUCTION the BCL2 inhibitor venetoclax has dramatically changed the treatment of chronic lymphocytic leukemia (CLL) and has introduced the concept of time-limited therapy with targeted agents. AREAS COVERED This review discusses the mechanism of action… read more here.
Keywords: lymphocytic leukemia; efficacy; venetoclax; treatment ... See more keywords